This study aims to better understand the functioning of the immune response to SARS CoV-2 in order to propose new treatments based on the body’s cellular response to COVID-19
The collaboration of all the centres involved will make it possible to demonstrate the relevance of T cells in the immune status of patients throughout the disease and provide new therapeutic tools in the absence of available anti-SARS-Cov2 treatments, and may provide knowledge and tools for other cellular immunotherapies beyond COVID-19.DR. MANEL JUAN
Description of the Study:
- Title: Development of therapies based on the cellular response to the virus.
- Principal Investigator: Manel Juan.
- Centres of Implementation: Hospital Clínic de Barcelona-IDIBAPS.
- Study Population: Patients who have already passed COVID-19.
- Type of Study: Multicentre.
– First, different immunological profiles associated with different clinical prognoses in patients who have passed COVID-19 will be identified, which will allow the detection of biomarkers capable of predicting the evolution of people with the infection.
– In addition, different proposals will be developed to provide useful cellular immunotherapies in the different phases of the infection. On the one hand, natural T cells obtained from samples of patients who have already passed COVID-19 will be used to stop the infection. At the same time, proposals for anti-SARS-CoV-2 specific chimeric antigenic receptors (CARs) will be developed by modifying the patient’s lymphocytes in the laboratory so that they are able to recognise and eliminate the virus. Proposals for the control of hyper-responsiveness through natural or post-manipulation regulatory T-lymphocytes will also be developed.
Objectives of the Study:
Principal Objective: To measure the cellular response capacity of the immune system against SARS-CoV-2, detecting and obtaining T lymphocytes that can act to combat COVID-19 in its different stages.
More about this Study:
Scientific Context: The SARS-CoV-2 coronavirus is a new type of coronavirus that was first detected in December 2019 in Wuhan City, Hubei Province, China. The disease, COVID-19, causes mild respiratory symptoms in eight out of 10 people, but can lead to severe respiratory disease, such as pneumonia, and even death.
Key to tackling this new disease is a thorough understanding of the immune status of the population against SARS-CoV-2 and the specific role of this immunity, i.e. the type of immunity and how long it is maintained.